Improving the Prognosis for Patients with BRAF-mutant, MSI-H Tumors
Are you current with the latest updates with MSI-H/dMMR and/or BRAF-mutant metastatic colorectal cancer? In this case-based activity, leading expert and researcher, Dr. Dung Le discusses the latest approvals and recommendations for patients with MSI-H/dMMR and/or BRAF-mutant mCRC. This activity also features interactive case presentations which involve biomarker testing, treatment selection, and mitigating potential adverse events.
Faculty: Dung Le, MD
Expiration Date: October 25, 2022
CME/CE is no longer available for this activity